Central nervous system involvement in systemic lupus erythematosus in a hospital-based study of 171 cases: The possible therapeutic role of intrathecal therapy

Journal of Clinical Rheumatology

Volumn 5, Issue 6, 1999, Pages 314-319

  Zhang, Xuan ^a   Dong, Yi ^a   Tang, Fu Lin ^a   Zhang, Fen Chun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Central nervous system; Intrathecal therapy; Systemic lupus erythematosus

Indexed keywords

DEXAMETHASONE; GLUCOSE; METHOTREXATE; PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; EPILEPSY; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROPSYCHIATRY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 2442745348     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-199912000-00003     Document Type: Article

References (14)

1. Wallace DJ, Metzger AL. Systemic lupus erythematosus and the nervous system. In: Dubois et al., eds. Systemic lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997. p. 723-53.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification on systemic lupus erythematosus (SLE). Arthritis Rheum 1982;25:1271-77.
3. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1994;99:153-63.
4. Bluestein HG. Antibodies to brain. In: Dubois et al., eds. Systemic lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997. p. 517-21
5. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus erythematosus and anti-P protein antibodies. N Engl J Med 1987;317;265.
6. Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J Exp Med 1985;162;459-65.
7. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991;90:54-62.
8. Isshi K, Hirohata S. Association of antiribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996;39:1483-9.
9. Zhang N-Z, Chen W-Z. Antineuronal antibodies in Chinese patients with neuropsychiatric SLE. In: Proceedings of the Second International Conference on Systemic Lupus Erythematosus. Tokyo: Professional Postgraduate Services; 1989. p. 101-11.
10. Spezialetti R, Peter JB, Bluestein HG. Clinical correlations between anti-ribosomal P and anti-neuronal cell antibodies in CNS-SLE. Arthritis Rheum 1990;33:S102-4.
11. Valesini G, Priori R, Francia A, Balestnieri G, Tincani A, Airo P, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.Ann Rew Immunopathol 1994;16:313-21.
12. De Vita S, Ferraccioli GF, Dipoi E, Bartoli E, Bombardieri S. High dose intravenous immunoglobulins therapy for rheumatic disease: clinic relevance and personal experience. Clin Exp Rheum 1996;14(S15):84-92.
13. Lin CY, Hsu HC ,Chian H. Improvement of histological and immunogical change in steroid and immunosuppressive drug-resistance lupus nephritis by high-dose intravenous gammaglobulins. Nephron 1989;53:303-10.
14. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulin in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996;23:71-5.